These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27660688)

  • 1. Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.
    Olson EJ; Lechtenberg BC; Zhao C; Rubio de la Torre E; Lamberto I; Riedl SJ; Dawson PE; Pasquale EB
    ACS Med Chem Lett; 2016 Sep; 7(9):841-6. PubMed ID: 27660688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
    Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
    ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
    Rué L; Oeckl P; Timmers M; Lenaerts A; van der Vos J; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Weishaupt JH; Ludolph AC; Otto M; Robberecht W; Lemmens R
    Acta Neuropathol Commun; 2019 Jul; 7(1):114. PubMed ID: 31300041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and Selective EphA4 Agonists for the Treatment of ALS.
    Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M
    Cell Chem Biol; 2017 Mar; 24(3):293-305. PubMed ID: 28196613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1
    Zhao J; Cooper LT; Boyd AW; Bartlett PF
    Sci Rep; 2018 Jul; 8(1):11393. PubMed ID: 30061574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic principle for designing antagonistic/agonistic molecules for EphA4 receptor, the only known ALS modifier.
    Qin H; Lim LZ; Song J
    ACS Chem Biol; 2015 Feb; 10(2):372-8. PubMed ID: 25334011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy.
    Poppe L; Smolders S; Rué L; Timmers M; Lenaerts A; Storm A; Schoonaert L; de Boer A; Van Damme P; Van Den Bosch L; Robberecht W; Lemmens R
    Front Neurosci; 2019; 13():1233. PubMed ID: 31803009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.
    Pegg CL; Cooper LT; Zhao J; Gerometta M; Smith FM; Yeh M; Bartlett PF; Gorman JJ; Boyd AW
    Sci Rep; 2017 Jul; 7(1):6519. PubMed ID: 28747680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine-extended anglerfish peptide YG (aPY) a neuropeptide Y (NPY) homologue may be a precursor of a biologically active peptide.
    Balasubramaniam A; Andrews PC; Renugopalakrishnan V; Rigel DF
    Peptides; 1989; 10(3):581-5. PubMed ID: 2780417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the EphA4 receptor in the nervous system with biologically active peptides.
    Murai KK; Nguyen LN; Koolpe M; McLennan R; Krull CE; Pasquale EB
    Mol Cell Neurosci; 2003 Dec; 24(4):1000-11. PubMed ID: 14697664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease.
    Vargas LM; Cerpa W; Muñoz FJ; Zanlungo S; Alvarez AR
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1148-1159. PubMed ID: 29378302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinase activity of EphA4 mediates homeostatic scaling-down of synaptic strength via activation of Cdk5.
    Peng YR; Hou ZH; Yu X
    Neuropharmacology; 2013 Feb; 65():232-43. PubMed ID: 23123677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EphA4 receptor shedding regulates spinal motor axon guidance.
    Gatto G; Morales D; Kania A; Klein R
    Curr Biol; 2014 Oct; 24(20):2355-65. PubMed ID: 25264256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease.
    Poppe L; Rué L; Timmers M; Lenaerts A; Storm A; Callaerts-Vegh Z; Courtand G; de Boer A; Smolders S; Van Damme P; Van Den Bosch L; D'Hooge R; De Strooper B; Robberecht W; Lemmens R
    Alzheimers Res Ther; 2019 Dec; 11(1):102. PubMed ID: 31831046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of a novel isoform of EphA4 and ITS expression in SOD1
    Zhao J; Boyd AW; Bartlett PF
    Neuroscience; 2017 Apr; 347():11-21. PubMed ID: 28153688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal RacGAP α-Chimaerin Is Required to Establish the Midline Barrier for Proper Corticospinal Axon Guidance.
    Katori S; Noguchi-Katori Y; Itohara S; Iwasato T
    J Neurosci; 2017 Aug; 37(32):7682-7699. PubMed ID: 28747385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glycine residue in cyclic lactam analogues of galanin(1-16)-NH2 is important for stabilizing an N-terminal helix.
    Carpenter KA; Schmidt R; Yue SY; Hodzic L; Pou C; Payza K; Godbout C; Brown W; Roberts E
    Biochemistry; 1999 Nov; 38(46):15295-304. PubMed ID: 10563815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphA4-dependent axon guidance is mediated by the RacGAP alpha2-chimaerin.
    Wegmeyer H; Egea J; Rabe N; Gezelius H; Filosa A; Enjin A; Varoqueaux F; Deininger K; Schnütgen F; Brose N; Klein R; Kullander K; Betz A
    Neuron; 2007 Sep; 55(5):756-67. PubMed ID: 17785182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of axonal EphA4 forward signaling is involved in the effect of EphA3 on chicken retinal ganglion cell axon growth during retinotectal mapping.
    Fiore L; Medori M; Spelzini G; Carreño CO; Carri NG; Sanchez V; Scicolone G
    Exp Eye Res; 2019 Jan; 178():46-60. PubMed ID: 30237102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.